Unknown

Dataset Information

0

Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden.

ABSTRACT:

SUBMITTER: Gong J 

PROVIDER: S-EPMC7670562 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
| S-EPMC5944039 | biostudies-literature
Unknown Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer.
| S-EPMC6209395 | biostudies-literature
Unknown The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
| S-EPMC4497957 | biostudies-literature
Unknown PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.
| S-EPMC5290437 | biostudies-literature
Unknown RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.
| S-EPMC5980384 | biostudies-literature
Unknown Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.
| S-EPMC6380009 | biostudies-literature
Unknown A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint.
| S-EPMC6136863 | biostudies-other
Unknown Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.
| S-EPMC5360064 | biostudies-literature
Unknown Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?
| S-EPMC8512471 | biostudies-literature
Unknown EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.
| S-EPMC6923667 | biostudies-literature